171 related articles for article (PubMed ID: 21258877)
1. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
[TBL] [Abstract][Full Text] [Related]
2. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
4. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
Wang J; Lü S; Yang J; Song X; Chen L; Huang C; Hou J; Zhang W
J Hematol Oncol; 2009 Jul; 2():32. PubMed ID: 19642997
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.
Jin J; Wang JX; Chen FF; Wu DP; Hu J; Zhou JF; Hu JD; Wang JM; Li JY; Huang XJ; Ma J; Ji CY; Xu XP; Yu K; Ren HY; Zhou YH; Tong Y; Lou YJ; Ni WM; Tong HY; Wang HF; Mi YC; Du X; Chen BA; Shen Y; Chen Z; Chen SJ
Lancet Oncol; 2013 Jun; 14(7):599-608. PubMed ID: 23664707
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
Tang J; Liu Y; Chen J; Xue H; Pan C; Gu L
Int J Hematol; 2011 May; 93(5):610-617. PubMed ID: 21509439
[TBL] [Abstract][Full Text] [Related]
8. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Wu L; Li X; Su J; He Q; Zhang X; Chang C; Pu Q
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia.
Zhang JY; Li L; Liu W; Jin Y; Zhao M; Zhou Y; Fan Z
Clin Transl Oncol; 2021 Jan; 23(1):48-57. PubMed ID: 32458310
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
14. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
[TBL] [Abstract][Full Text] [Related]
15. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
16. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
Reagan JL; Sullivan MR; Winer ES; Lansigan F; Cardin MS; Castillo JJ
Leuk Res; 2015 Aug; 39(8):812-7. PubMed ID: 26045177
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of Different Doses of Daunorubicin Induced Chemotherapy in Patients with Newly Diagnosed Primary Acute Myeloid Leukemia Under 65 Years Old].
Gong SG; Wang FJ; Wang ST; Zheng Q; Shuai X; Ma HB; Zhang L; Chen XC; Wu Y; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1071-1079. PubMed ID: 34362484
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
Xiao Z; Xue H; Li R; Zhang L; Yu M; Hao Y
Am J Hematol; 2008 Mar; 83(3):203-5. PubMed ID: 17874451
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
[TBL] [Abstract][Full Text] [Related]
20. Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
Liu H; Zhang J; Ren S; Chen M; Liu L; Zhang H
Leuk Lymphoma; 2017 Nov; 58(11):2758-2761. PubMed ID: 28406352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
